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SUPPLEMENTARY NOTES
14. ABSTRACT We hypothesized that MUC1, a transmembrane glycoprotein that is overexpressed in >80% of pancreatic ductal adenocarcinoma induces a pro-angiogenic tumor microenvironment by increasing the level of NRP-1 and VEGF thereby enhancing angiogenesis and metastasis. We report that MUC1 hi PC cells and tumors in vitro and in vivo not only express higher levels of NRP1 but also express higher levels of VEGFR2, pVEGFR2 1175 , pVEGFR2 996 , and VEGFR3 as well as secrete higher levels of VEGF than MUC1 low PC cells. This enables the MUC1 hi /NRP hi cells to generate long ectopic blood vessels and enhanced distant metastasis. In the proposal, we also hypothesized that blocking the interaction between VEGF 165 and NRP-1 within the tumor microenvironment will lead to therapeutic benefit. Indeed, in vivo blocking NRP1 significantly reduces tumor burden in the MUC1 hi tumors. In fact 4 out of 7 mice had a complete response, 2 had small tumors and 1 mouse did not respond and developed large tumor. This treatment had no significant effect on the MUC1 low tumors. This is not surprising since MUC1 low tumors have very low levels of NRP1 and VEGFR2. It should be noted that these MUC1 low tumors do however grow but may eventually form stable disease. Thus, we conclude that NRP1 may be a promising target for MUC1 hi PC and in the future conjugating to the MUC1 antibody for targeted delivery may enhance its potency. Introduction: Pancreatic cancer is a lethal disease. We hypothesize that MUC1 induces a pro-angiogenic tumor microenvironment by increasing the level of NRP-1, thus enhancing angiogenesis, disease progression and metastases. Second, blocking the interaction between VEGF 165 and NRP-1 within the tumor microenvironment will lead to therapeutic benefit. We report progress for all three tasks that we had proposed. I have thus broken the report down by tasks. The objective and specific aims are stated below. This is followed by the individual tasks with the progress made for that task. We show 11 figures in total. Figures 1-3 
SUBJECT TERMS
Objectives/Specific Aims:
To test the effects of MUC1+ve PC cells on in vitro endothelial cell function in an NPR-1-dependent fashion.
To determine if MUC1 up-regulates NRP-1 and creates a pro-angiogenic niche in vivo.
To directly target angiogenesis within the tumor microenvironment by using TAB 004 MUC1 antibody conjugated to a peptide blocking VEGF-NPR-1 binding.
Task 1:
1) To test the effects of MUC1 + PC cells on in vitro endothelial cell function in an NRP-1-dependent fashion (0-9 months). For this task we perform in vitro angiogenesis assays to assess the ability of MUC1-expressing pancreatic cells to enhance endothelial cell proliferation, invasion and tube formation via NRP-1 Thus, we first determined if a correlation exists between in MUC1 and NRP1 in a panel of human PDA cell lines that endogenously express high or low MUC1. Next we determined if MUC1 regulates NRP1 expression by conducting gain of function (stably transfected full length MUC1 in MUC1-low cells) and loss of function studies (by knocking down MUC1 using MUC1 specific siRNA). Figure 1A clearly shows that cells expressing high endogenous MUC1 also have high NRP1 while cells with low endogenous MUC1 has low NRP with a few exceptions (Su86.86 and Panc1). We show that overexpressing full length MUC1 in two separate MUC1low cell lines (BxPC3 and Panc) can induce higher expression of NRP1 ( Figure 1B ) while knocking down MUC1 from two other MUC1hi cell lines (CFPAC and HPAFII) can reduce NRP1 expression. Whether this regulation is direct or indirect is not yet delineated.
Next we studied whether the MUC1hi/NRP1hi cells affects formation of ectopic blood vessel (number and length) in a zebra fish embryo model of angiogenesis [1] [2] . We show for the first time that human PDA cell line BxPC3.MUC1 induces significantly more and longer vessels in vivo in a zebra fish embryo model than its counterpart BxPC3.Neo cells (Figure 2A-C) . Furthermore, we show that BxPC3.MUC1 tumors are highly invasive and form significantly more metastasis compared to BxPC3.Neo tumors ( Figure 3A and B) clearly suggesting that the tumors with high MUC1 can enhance proliferation by affecting vessel formation. We will confirm this result in an in vitro tube formation assay. However we believe that the in vivo assay is more relevant and does not depend on the matrigel and the type of endothelial cells used. Quantitative measurement of the length of the ectopic vessels formed in the embryo (n=100 embryos each). t test*p=0.005 between BxPC3.Neo and BxPC3.MUC1.
A.
B. C.
Ctrl To determine if MUC1 up-regulates NRP-1 and creates a pro-angiogenic niche in vivo (0-18 months). For Task 2, we will use our mouse models of pancreatic cancer to determine if MUC1-expressing pancreatic tumors have enhanced intra-tumoral levels of NRP-1 and angiogenesis.
We first demonstrate that expression of NRP1 is significantly higher in the spontaneously arising PDA tumors in WT (Muc1 intact) versus PDA in Muc1 null mice ( Figure 4A ) [3] . Cell lines from these tumors were developed and NRP1 and Muc1 levels tested by western blotting and flow cytometry ( Figure 4B and C) and confirm the data in Figure 4A . We then determined that knocking down NRP1 with specific siRNA significantly reduces proliferation only in Muc1 expressing KC cells but not in KCKO cells suggesting for the first time that Muc1-ve tumors are not dependent on NRP1 for their growth but Muc1+ve tumors are ( Figure 4D and E).
To further elucidate the mechanism, we determined the other VEGF receptor levels as well as secreted VEGF levels in these cells. This is especially important as NRP1 is only a co-receptor of VEGF and signaling through VEGFR is critical for the angiogenic signaling to occur [4] . We show that KCKO (Muc1 null) cells have moderately lower levels of VEGF receptor 1, 2, and 3 than its counterpart KC cells which have an intact Muc1 ( Figure 5A ). Further, KC cells secrete significantly higher levels of VEGF than KCKO cells ( Figure 5B ). It must be noted that in human cell line BxPC3.MUC1, there was only an increase in VEGFR 2 from its counterpart BxPC3.Neo. There was no effect on levels of VEGFR1 and VEGFR3 was absent in these cells ( Figure 5C ). We have already shown previously that BxPC3.MUC1 cells express high levels of several pro-angiogenic factors compared to BxPC3.Neo cells [5] . Why this difference between mouse and human cells in VEGFR is not clear at this time. NRP1 levels are always lower in Muc1/MUC1 low cells compared to Muc1/MUC1hi cells.
Next we studied if supernatant from these KC and KCKO cells can differentially regulate the NRP1 levels of murine endothelial cells, 2H11. As shown in Figure 6A , 2H11 cells endogenously express high levels of NRP1 and VEGFR1 but low levels of VEGFR2 and 3 ( Figure 6A ). However, stimulating with supernatant had no effect on the NRP1 levels as tested by flow cytometry ( Figure 6B and C). We did not test the other VEGF receptors and are planning to conduct those analyses soon. Other endothelial cell lines will also be tested similarly. Even though it might not affect NRP1 levels, it is possible that there will be differential angiogenic/oncogenic signaling. VEGFR-2, the major positive signal transducer for both physiological and pathological angiogenesis is selectively expressed on vascular endothelial cells. The binding of VEGF to its receptors induces dimerization and subsequent receptor phosphorylation, which then leads to the activation of several intracellular downstream signaling pathways promoting angiogenesis [6] . Thus we looked at the levels of VEGFR2 phosphorylation in vivo in KC and KCKO tumors. It was of great interest to demonstrate that not only are the levels of NRP1 and VEGFR2 significantly lower in the KCKO tumors, the phosphotylation at tyrosines 1175, and 996 are significantly low ( Figure 7 ). This is of course because the receptor level itself is low but phosphorylation of tyrosine 996 is completely absent in KCKO tumors as compared to the KC tumors suggesting that KCKO tumors that lack MUC1 regulate NRP1 and VEGFR2 and thereby downregulate the angiogenic signaling. The question still remains whether the low receptors are due to low endothelial cells and low vessels or due to the tumor cells themselves as NRP1 and VEGFR are expressed on both the epithelial and the endothelial cells. This will be studied in great detail in the coming year. This also explains why KC cells were the only ones that responded to NRP siRNA and showed significantly lower proliferation in vitro ( Figure 4E ). This is significant since NRP1 binds VEGF-A 165 and only when co-expressed with VEGFR2, it enhances the binding of VEGF-A 165 to VEGFR-2 by 4-to 6-fold and results in sustained vascular permeability, inflammation, and endothelial cell migration. Task 3: To directly target angiogenesis within the tumor microenvironment by using TAB 004 conjugated to an inhibitory peptide that blocks VEGF- NPR-1 interaction (12-24 months) . In this aim, we will attempt targeted drug delivery using an antibody specific for tumor-associated MUC1 (TAB 004) conjugated to a peptide inhibitor of VEGF-NRP-1 binding.
Before we injected the cells in vivo, we first confirmed that BxPC3.MUC1 tumor cells proliferate at a significantly higher rate than BxPC3.Neo ( Figure 8A ). Next we show that the tumors in vivo recapitulate the in vitro finding that MUC1-expressing cells express more NRP1 and VEGF ( Figure  8B ). Finally tumor bearing mice were treated with the NRP1 blocking peptide. To determine what downstream factors may be altered due to the ineffective NRP1/VEGF signaling axis and contribute to the difference observed in angiogenesis between MUC1hi and low cells, we conducted a multiplex bioassay on tumor derived conditioned media. The most change was observed in Leukocyte Inhibitory Factor (LIF) (Figure 9 ). LIF inhibits angiogenesis in vitro, an effect that can be correlated with a LIF-mediated decrease in endothelial cell proliferation, migration and extracellular proteolysis [7] . LIF was lower both in the supernatant of BxPC3.MUC1 and HPAF cells compared to BxPC3.Neo and HPAF cells treated with MUC1siRNA. In contrast, MMP2 was higher in the BxPC3.MUC1 cell supernatant. This data is significant as it is the first indication of LIF being involved in tumor progression and angiogenesis in pancreatic cancer. Finally, with regard to targeted drug delivery using the TAB 004 MUC1 monoclonal antibody, we first show that TAB 004 when injected intra peritoneal and intravenously specifically reaches the tumor within 24hours (Figure 10) . With iv injection, we observe some reaching the spleen. Therefore, for our future experiments, we plan to inject the antibody intraperitoneal. Second, we show by in vitro confocal analysis that TAB 004 is internalized into KCM cells through endocytosis (Figure 11 ). Thus, we have shown that the blocking peptide is effective in vivo and that targeting antibody internalizes in the cells and reaches the tremor bed in vivo. Now we are ready to conjugate the blocking peptide to the antibody and start the treatment in the following year. 
Conclusion
In conclusion, we show that NRP1 may be an excellent target for treating MUC1+ve PDA but not MUC1-ve PDA. The mechanistic role of LIF needs to be further studied. If LIF indeed is the underlying anti-angiogenic signal for MUC1-ve pancreatic cancer, we can envision the potential therapeutic application of LIF1 therapy. It is doubtful that a monotherapy with NRP1 blockade will work and therefore using the TAB 004-conjugated to the drug may show promise due to ADCC caused by the antibody and thereby making the tumors more vulnerable to NRP1 blockade. In the long term, combination therapy with standard of care drug and NRP1 blockade conjugated to TAB 004 or two drugs packaged in nanoparticles and conjugated to the antibody might be highly efficacious for patients with pancreatic cancer.
